About 60% of all pregnancies take place in malaria endemic areas . In addition, pregnant women and children are the most vulnerable group for malaria infection leading to higher morbidity and mortality. Although studies on the efficacy of antimalarials have been conducted extensively, pregnant women have been excluded from the majority of clinical trials in the past, mainly because of safety concerns for the fetus. Due to the lack of evidence, quinine, rather than artemisinin combination therapy (ACT), has been recommended as the first-line treatment for pregnant women in the first trimester by the World Health Organization (WHO) . However, recent studies measuring the efficacy and safety of artemisinin derivatives during pregnancy, including in the first trimester , have shown reassuring results . ACT may be recommended as a first-line treatment option for pregnant women regardless of the trimester in the new WHO guideline . As the current treatment recommendation for pregnant women is based on limited available data, vigorous and prompt assessment of efficacy in pregnancy is warranted . The WorldWide Antimalarial Resistance Network (WWARN) has established an individual participant data (IPD) sharing platform. We are aiming to expand the platform to include both published and unpublished studies exploring the impact of malaria infection during pregnancy (MIP).